Study of the activation mechanism of human GRF(1-29)NH2 on rat mast cell histamine release.

Estévez MD, Alfonso A, Vieytes MR, Louzao MC, Botana LM

Inflammation research : official journal of the European Histamine Research Society ... [et al.]1 Feb 1995Cited by 5 (Europe PMC)

PMID7544679DOI10.1007/bf01793219PepBankPUB-07544679

Publisher page PubMedAsk about this study

Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

4 results from studies that gave the peptide. No result from this study comes from people.

01LabIn vitro (cells)Mechanism
Human GRF(1-29)NH2 released histamine from rat pleural and peritoneal mast cells by a non-cytotoxic, non-immunological mechanism.
In plain wordsIn rat cells, human GRF(1-29)NH2 made mast cells release histamine without killing the cells.
Peptide
Sermorelin
Outcome
IncreaseHistamine release
Study
ratn: not reported in source
rat pleural and peritoneal mast cells
Outcome group
Immune response · Immune and inflammation
Studied dose
Dose not stated
Source sentences
Summary
Human growth releasing factor (GRF) (1-29)NH2 releases histamine from pleural and peritoneal rat mast cells by a non cytotoxic and non immunological mechanism.
Report a problemFND-0754467901
02LabIn vitro (cells)Mechanism
The response of rat mast cells to human GRF did not depend on extracellular calcium.
In plain wordsIn rat cells, the histamine response to human GRF did not need calcium from outside the cell.
Peptide
Sermorelin
Outcome
No significant changeDependence on extracellular calcium
Study
ratn: not reported in source
rat pleural and peritoneal mast cells
Outcome group
Immune response · Immune and inflammation
Studied dose
Dose not stated
Source sentences
Summary
The response to human GRF does not depend on extracellular calcium
Report a problemFND-0754467907
03LabIn vitro (cells)Mechanism
Histamine release from rat mast cells in response to human GRF correlated well with 45calcium uptake.
In plain wordsIn rat cells, the amount of histamine released after human GRF was linked to calcium uptake.
Peptide
Sermorelin
Outcome
Not applicableHistamine release and 45calcium uptake
Study
ratn: not reported in source
rat pleural and peritoneal mast cells
Outcome group
Immune response · Immune and inflammation
Studied dose
Dose not stated
Source sentences
Summary
but there is a good correlation between the percent of histamine released and 45calcium uptake.
Report a problemFND-0754467908
04LabIn vitro (cells)Mechanism
The kinetics of calcium uptake in rat mast cells were fast, with maximum uptake reached in 30 seconds.
In plain wordsIn rat cells, calcium uptake was fast and reached its maximum in 30 seconds.
Peptide
Sermorelin
Outcome
Not applicableCalcium uptake kinetics
Study
ratn: not reported in source
rat pleural and peritoneal mast cells
Outcome group
Immune response · Immune and inflammation
Studied dose
Dose not stated
Measurements
Time to maximum calcium uptake
30 seconds
rat mast cells
Source sentences
Summary
The kinetic of calcium uptake is fast, maximum uptake being reached in 30 seconds.
Report a problemFND-0754467909

Studies that did not test the peptide alone5

In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Sermorelin.

05LabNot a test of Sermorelin aloneIn vitro (cells)Mechanism
Pretreatment of rat mast cells with pertussis toxin markedly inhibited GRF-induced secretion.
In plain wordsIn rat cells, pertussis toxin strongly reduced histamine release triggered by GRF.
Peptide
Sermorelin
Outcome
DecreaseGRF-induced secretion after pertussis toxin
Study
ratn: not reported in source
rat pleural and peritoneal mast cells
Outcome group
Immune response · Immune and inflammation
Source sentences
Summary
Pretreatment of cells with pertussis toxin markedly inhibits the secretion, suggesting a possible function of a Gi-protein in the activation pathway.
In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.
Report a problemFND-0754467902
06LabNot a test of Sermorelin aloneIn vitro (cells)Mechanism
IBMX, which raises cAMP, inhibited GRF-mediated mediator secretion in rat mast cells.
In plain wordsIn rat cells, IBMX reduced histamine release triggered by GRF.
Peptide
Sermorelin
Outcome
DecreaseGRF-induced histamine release after IBMX
Study
ratn: not reported in source
rat pleural and peritoneal mast cells
Outcome group
Immune response · Immune and inflammation
Source sentences
Summary
IBMX inhibits mediator secretion
In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.
Report a problemFND-0754467903
07LabNot a test of Sermorelin aloneIn vitro (cells)Mechanism
Cholera toxin did not modify GRF-mediated histamine release in rat mast cells.
In plain wordsIn rat cells, cholera toxin did not change histamine release triggered by GRF.
Peptide
Sermorelin
Outcome
No significant changeGRF-induced histamine release after cholera toxin
Study
ratn: not reported in source
rat pleural and peritoneal mast cells
Outcome group
Immune response · Immune and inflammation
Source sentences
Summary
in contrast, cholera toxin is ineffective to modify histamine release.
In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.
Report a problemFND-0754467904
08LabNot a test of Sermorelin aloneIn vitro (cells)Mechanism
The PKC activator TPA amplified the response of rat mast cells to human GRF and shifted the dose-response curve to the left.
In plain wordsIn rat cells, TPA made the cells respond more strongly to human GRF.
Peptide
Sermorelin
Outcome
IncreaseGRF dose-response after TPA
Study
ratn: not reported in source
rat pleural and peritoneal mast cells
Outcome group
Immune response · Immune and inflammation
Source sentences
Summary
The PKC activator TPA amplifies the response of mast cells to human GRF, shifting the dose-response curve to the left.
In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.
Report a problemFND-0754467905
09LabNot a test of Sermorelin aloneIn vitro (cells)Mechanism
The phosphatase inhibitor okadaic acid had no effect on the dose-response curve of rat mast cells to GRF.
In plain wordsIn rat cells, okadaic acid did not change the response to GRF.
Peptide
Sermorelin
Outcome
No significant changeGRF dose-response after okadaic acid
Study
ratn: not reported in source
rat pleural and peritoneal mast cells
Outcome group
Immune response · Immune and inflammation
Source sentences
Summary
The pretreatment of mast cells with the phosphatase inhibitor okadaic acid exerts no effect on the dose-response function curve to GRF.
In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.
Report a problemFND-0754467906

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
10 Oct 2026, 10:21 UTC
Study results updated
Version 1
9 Oct 2026, 03:13 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.